A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
Financial Summary
| Share Statistics | VRXA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $216.4 | $289.2 | 28% |
|
| Shares Out (Mil) | na | 54.1 | na |
|
| Institutional Ownership | 1.6% | 93.1% | 3% |
|
| Float (Mil) | 105.2 | 42.2 | 62% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 318 | 451 | 52% |
|
| Price Change (52-week) |
na | 59.8% | na |
|
| Growth | VRXA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | VRXA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($84) | ($43) | 12% |
|
| EPS (TTM) | ($5.804) | ($1.500) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | na | ($31) | na |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | na | $4 | na |
|
| Enterprise Value (Q1) (Mil) | na | $190 | na |
|
| Valuation | VRXA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.84 | na |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VRXA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 66.0% | 66.9% | 78% |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | na | (47.8%) | na |
|
| ROE | na | (55.0%) | na |
|
| Liabilities to Assets | na | 29.7% | na |
|
| F-Score | 0 | 3 | na |
|
Veraxa Biotech AG did not pass any screens on 9/3/2026.
